MX350304B - Metodos para reducir la ingesta excesiva o comer compulsivamente. - Google Patents

Metodos para reducir la ingesta excesiva o comer compulsivamente.

Info

Publication number
MX350304B
MX350304B MX2013006070A MX2013006070A MX350304B MX 350304 B MX350304 B MX 350304B MX 2013006070 A MX2013006070 A MX 2013006070A MX 2013006070 A MX2013006070 A MX 2013006070A MX 350304 B MX350304 B MX 350304B
Authority
MX
Mexico
Prior art keywords
methods
binge
compulsive eating
reducing
bupropion
Prior art date
Application number
MX2013006070A
Other languages
English (en)
Other versions
MX2013006070A (es
Inventor
Eduardo Dunayevich
Susan Mcelroy
Ron Landbloom
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350304(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of MX2013006070A publication Critical patent/MX2013006070A/es
Publication of MX350304B publication Critical patent/MX350304B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se describen en la presente composiciones, usos, equipos y métodos para reducir la ingesta excesiva o comer compulsivamente. Los métodos pueden incluir administrar una combinación efectiva de una dosis de un bupropion o una sal farmacéuticamente aceptable del mismo y una dosis de naltrexona o una sal farmacéuticamente aceptable de la misma. Los métodos pueden incluir identificar a un paciente que tiene sobrepeso u obesidad y proporcionar al paciente una combinación efectiva de bupropion y naltrexona. Los métodos pueden incluir reducir el número de eventos de ingesta excesiva o de comer compulsivamente. Los métodos pueden incluir reducir la severidad de los eventos de ingesta excesiva o de comer compulsivamente.
MX2013006070A 2010-12-03 2011-12-02 Metodos para reducir la ingesta excesiva o comer compulsivamente. MX350304B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41935410P 2010-12-03 2010-12-03
PCT/US2011/063170 WO2012075453A1 (en) 2010-12-03 2011-12-02 Methods for reducing binge or compulsive eating

Publications (2)

Publication Number Publication Date
MX2013006070A MX2013006070A (es) 2013-07-29
MX350304B true MX350304B (es) 2017-09-04

Family

ID=46172302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006070A MX350304B (es) 2010-12-03 2011-12-02 Metodos para reducir la ingesta excesiva o comer compulsivamente.

Country Status (26)

Country Link
US (2) US20130252995A1 (es)
EP (1) EP2646011B1 (es)
JP (1) JP2014508717A (es)
KR (1) KR20140035319A (es)
CN (1) CN103298462A (es)
AR (2) AR084093A1 (es)
AU (3) AU2011336298B2 (es)
BR (1) BR112013015957B1 (es)
CA (1) CA2819003A1 (es)
CL (1) CL2013001565A1 (es)
CY (1) CY1119560T1 (es)
DK (1) DK2646011T3 (es)
ES (1) ES2647232T3 (es)
HR (1) HRP20171678T1 (es)
HU (1) HUE034641T2 (es)
IL (1) IL226483A0 (es)
LT (1) LT2646011T (es)
MX (1) MX350304B (es)
NO (1) NO2646011T3 (es)
PL (1) PL2646011T3 (es)
PT (1) PT2646011T (es)
RS (1) RS56548B1 (es)
RU (1) RU2620913C2 (es)
SI (1) SI2646011T1 (es)
TW (2) TWI536986B (es)
WO (1) WO2012075453A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197250C2 (ru) * 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2009080691A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
CA2817071C (en) * 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors

Also Published As

Publication number Publication date
CA2819003A1 (en) 2012-06-07
AU2017202793A1 (en) 2017-05-18
IL226483A0 (en) 2013-07-31
TWI536986B (zh) 2016-06-11
HUE034641T2 (en) 2018-02-28
RS56548B1 (sr) 2018-02-28
EP2646011A4 (en) 2014-04-23
SI2646011T1 (en) 2018-01-31
AU2011336298A1 (en) 2013-07-11
MX2013006070A (es) 2013-07-29
WO2012075453A1 (en) 2012-06-07
AU2018203921A1 (en) 2018-06-21
TW201228659A (en) 2012-07-16
AU2011336298B2 (en) 2017-03-02
HRP20171678T1 (hr) 2017-12-15
BR112013015957A2 (pt) 2019-10-29
AR124497A2 (es) 2023-04-05
AR084093A1 (es) 2013-04-17
JP2014508717A (ja) 2014-04-10
RU2620913C2 (ru) 2017-05-30
RU2013127420A (ru) 2015-01-10
CL2013001565A1 (es) 2014-04-04
TW201735912A (zh) 2017-10-16
LT2646011T (lt) 2017-11-10
ES2647232T3 (es) 2017-12-20
DK2646011T3 (da) 2017-11-20
KR20140035319A (ko) 2014-03-21
NO2646011T3 (es) 2018-01-13
US20130252995A1 (en) 2013-09-26
PT2646011T (pt) 2017-11-17
EP2646011A1 (en) 2013-10-09
AU2017202793B2 (en) 2018-03-08
CN103298462A (zh) 2013-09-11
CY1119560T1 (el) 2018-03-07
PL2646011T3 (pl) 2018-01-31
BR112013015957B1 (pt) 2021-07-20
EP2646011B1 (en) 2017-08-16
US20210283126A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MX350304B (es) Metodos para reducir la ingesta excesiva o comer compulsivamente.
IN2012DN02805A (es)
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
NZ601167A (en) Treatment of cardiac conditions
TN2011000414A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof
WO2011017484A3 (en) Sublingual and buccal film compositions
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
MX2010004281A (es) Composiciones y metodos para el tratamiento de la retinopatia diabetica.
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NZ625440A (en) Anti-cxcr1 compositions and methods
WO2011157416A3 (de) Transdermale verabreichung von memantin
MX354125B (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
NZ589733A (en) Oral administration of peripherally-acting opioid antagonists
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
NZ601383A (en) Methods and compositions for improved nerve conduction velocity
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения

Legal Events

Date Code Title Description
FG Grant or registration